Indication
As an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive (AChR-Ab+).
Medicine details
- Medicine name:
- efgartigimod alfa (Vyvgart)
- SMC ID:
- SMC2752
- Pharmaceutical company
- argenx
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 07 April 2025